Siegel RL et al (2022) Cancer statistics, 2022. CA: Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

Article  PubMed  Google Scholar 

Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Nakatsukasa K et al (2017) Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Breast Cancer 24(1):63–68. https://doi.org/10.1007/s12282-016-0666-7

Article  PubMed  Google Scholar 

Marra A, Curigliano G (2021) Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J 27(1):41–49. https://doi.org/10.1097/ppo.0000000000000498

Article  CAS  PubMed  Google Scholar 

Baker J et al (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1):49–59. https://doi.org/10.1016/j.ejon.2008.10.003

Article  PubMed  Google Scholar 

Nicolella D et al (1996) Weekly low dose epirubicin in elderly cancer patients. Tumori 82(4):369–371. https://doi.org/10.1177/030089169608200414

Article  CAS  PubMed  Google Scholar 

Gori S et al (2006) Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori 92(4):364–365. https://doi.org/10.1177/030089160609200421

Article  PubMed  Google Scholar 

Morgan GJ, Davies FE (2013) Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 88(Suppl 1):S14-22. https://doi.org/10.1016/j.critrevonc.2013.05.012

Article  PubMed  Google Scholar 

Tamura T et al (2016) A phase i trial of 100 mg/m2 docetaxel in patients with advanced or recurrent breast cancer. Acta Med Okayama 70(5):425–427. https://doi.org/10.18926/amo/54607

Article  PubMed  Google Scholar 

Muth M et al (2021) Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 87(2):306–316. https://doi.org/10.1111/bcp.14678

Article  CAS  PubMed  Google Scholar 

Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45(3):235–252. https://doi.org/10.2165/00003088-200645030-00002

Article  CAS  PubMed  Google Scholar 

Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114. https://doi.org/10.2165/00003088-199936020-00002

Article  CAS  PubMed  Google Scholar 

Shirakawa K et al (1999) Interaction of docetaxel (“Taxotere”) with human P-glycoprotein. Jpn J Cancer Res 90(12):1380–1386. https://doi.org/10.1111/j.1349-7006.1999.tb00723.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dyshlovoy SA et al (2022) New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein. Sci Rep 12(1):13570. https://doi.org/10.1038/s41598-022-17447-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vredenburg G et al (2015) Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett 232(1):182–192. https://doi.org/10.1016/j.toxlet.2014.11.005

Article  CAS  PubMed  Google Scholar 

de Jonge ME et al (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44(11):1135–1164. https://doi.org/10.2165/00003088-200544110-00003

Article  PubMed  Google Scholar 

Yule SM et al (2001) Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 47(3):222–228. https://doi.org/10.1007/s002800000220

Article  CAS  PubMed  Google Scholar 

Martin H et al (2003) Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 20(4):557–568. https://doi.org/10.1023/a:1023234429596

Article  CAS  PubMed  Google Scholar 

Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4(3):425–439. https://doi.org/10.1200/jco.1986.4.3.425

Article  CAS  PubMed  Google Scholar 

Tariq M et al (2016) Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations. Drug Deliv 23(8):2990–2997. https://doi.org/10.3109/10717544.2015.1136713

Article  CAS  PubMed  Google Scholar 

Liu K et al (2021) Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. Transl Oncol 14(1):100876. https://doi.org/10.1016/j.tranon.2020.100876

Article  CAS  PubMed  Google Scholar 

Lindley C et al (2002) The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30(7):814–822. https://doi.org/10.1124/dmd.30.7.814

Article  CAS  PubMed  Google Scholar 

Eksborg S (1989) Pharmacokinetics of anthracyclines. Acta Oncol 28(6):873–876. https://doi.org/10.3109/02841868909092323

Article  CAS  PubMed  Google Scholar 

Ismail M et al (2020) Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20(1):335. https://doi.org/10.1186/s12885-020-06855-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodrigues J et al (2023) Mitigating the risk of drug interactions in cancer patients taking oral anticancer agents: the role of a multidisciplinary team-based medication reconciliation. Cureus 15(2):e35324. https://doi.org/10.7759/cureus.35324

Article  PubMed  PubMed Central  Google Scholar 

Mueller-Schoell A et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77(4):441–464. https://doi.org/10.1007/s00228-020-03014-8

Article  PubMed  Google Scholar 

Fahmy A et al (2021) Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. Expert Opin Drug Metab Toxicol 17(7):803–821. https://doi.org/10.1080/17425255.2021.1943357

Article  CAS  PubMed  Google Scholar 

Lin W et al (2022) Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory. Ind Acad Perspect Pharm Res 39(8):1701–1731. https://doi.org/10.1007/s11095-022-03274-2

Article  CAS  Google Scholar 

Kuepfer L et al (2016) Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol 5(10):516–531. https://doi.org/10.1002/psp4.12134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowland Yeo K et al (2011) Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43(3):160–173. https://doi.org/10.1016/j.ejps.2011.04.008

Article  CAS  PubMed  Google Scholar 

Sudsakorn S et al (2020) 2020 FDA drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists. Curr Drug Metab 21(6):403–426. https://doi.org/10.2174/1389200221666200620210522

Article  CAS  PubMed  Google Scholar 

Mendes MS et al (2020) A physiologically based pharmacokinetic—pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. Eur J Pharm Sci 150:105355. https://doi.org/10.1016/j.ejps.2020.105355

Article  CAS  PubMed  Google Scholar 

Cheeti S et al (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34(3):141–154. https://doi.org/10.1002/bdd.1830

Article  CAS  PubMed  Google Scholar 

Baker SD et al (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10(24):8341–8350. https://doi.org/10.1158/1078-0432.Ccr-04-1371

Article  CAS  PubMed  Google Scholar 

Peng B et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22(5):935–942. https://doi.org/10.1200/jco.2004.03.050

Article  CAS